Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2019-05-09 Report Publication Anno…
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon will present at Anglonordic Life Science Conference
Report Publication Announcement Classification · 99% confidence The document is very short (550 characters) and announces that Biotec Pharmacon will present at the Anglonordic Life Science Conference and explicitly states, 'Please find the presentation attached.' This structure—an announcement about an event/presentation where the material is attached or linked—strongly suggests this is an announcement regarding the presentation material rather than the presentation itself or a major regulatory filing. Since 'Investor Presentation' (IP) is for the presentation content, and this is an announcement about it, the most appropriate classification based on the provided definitions and the 'MENU VS MEAL' rule is Report Publication Announcement (RPA), as it announces the availability of related material (the presentation). If RPA were not available, RNS would be the fallback, but RPA fits the context of announcing a published document/presentation.
2019-05-09 English
Biotec Pharmacon Q1 2019 Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Q1 2019 Presentation' and contains slides detailing financial highlights, segment performance (ArcticZymes and BetaGlucans), and strategic outlook for the first quarter of 2019. It is clearly a slide deck used for investor communication regarding quarterly results, which fits the definition of an Investor Presentation. Q1 2019
2019-04-30 English
Biotec Pharmacon Q1 2019 Presentation
Report Publication Announcement Classification · 98% confidence The document text is very short (478 characters) and explicitly states that the company is presenting its 'interim report for the first quarter of 2019' and that the 'presentation [is] attached'. This structure—announcing the release of a report (Q1 interim report) and providing the presentation material—fits the definition of a Report Publication Announcement (RPA), as it is an announcement about the publication of financial results/presentation, rather than the full report itself (which would likely be classified as IR if comprehensive). The presence of 'Q1 2019 Presentation' and the reference to the interim report strongly suggest this is the announcement material.
2019-04-30 English
Biotec Pharmacon Q1 2019 Report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Biotec Pharmacon ASA for Q1 2019. It includes detailed financial statements (Consolidated Statement of Profit & Loss), operational reviews, management commentary, and key performance indicators. It is not an announcement of a report (RPA) or a simple earnings release (ER), as it contains substantive financial data and analysis covering the full quarter. Therefore, it is classified as an Interim/Quarterly Report. Q1 2019
2019-04-30 English
Biotec Pharmacon Q1 2019 Report
Earnings Release Classification · 98% confidence The document is titled "Biotec Pharmacon Q1 2019 Results" and provides key financial highlights (sales, gross profit, EBITDA, cash-flow) for the first quarter ending March 31, 2019. This content structure is characteristic of an initial announcement of periodic financial results, which aligns with the definition of an Earnings Release (ER). Although it mentions a presentation and that the full report will be available elsewhere, the primary content provided here is the summary of the quarterly performance, making ER the most appropriate classification over RPA or RNS, given the substantial financial data presented. Q1 2019
2019-04-30 English
Biotec Pharmacon Q1 2019 Report
Earnings Release Classification · 100% confidence The document is titled "Biotec Pharmacon Q1 2019 Report" and provides key financial highlights (sales, gross profit, EBITDA, cash-flow) for the first quarter ending March 31, 2019. This content structure—a summary of period-specific financial results and management commentary—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it presents the core results and highlights immediately, it fits the definition of an Earnings Release (ER). The document also mentions that the full results, report, and presentation will be available elsewhere, suggesting this text itself is the initial announcement, reinforcing the ER classification over the comprehensive IR classification, although the line is thin. Given the focus on 'Highlights for Q1 2019' and the CEO's comments, ER is the most appropriate fit for this initial summary announcement. Q1 2019
2019-04-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.